The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA

U.S. & Europe Evaluate Abaloparatide Injection & Europe Approves Marketing Baricitinib for RA

April 11, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Abaloparatide Injection Evaluated in the U.S. & Europe
Abaloparatide, a synthetic injectable peptide that affects the parathyroid hormone receptor (PTH1 receptor), has completed Phase 3 clinical trials as a daily, self-administered injection (abaloparatide-SC). The U.S. Food and Drug Administration (FDA) is currently evaluating abaloparatide for its bone-building activity as a potential treatment for postmenopausal women with osteoporosis who have an increased fracture risk. A New Drug Application for abaloparatide-SC was submitted to the FDA in the first quarter of 2016, and its Prescription Drug User Fee Act date has been extended to June 30, 2017.1

You Might Also Like
  • Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis
  • FDA Approves Baricitinib for RA Patients
  • EU Approves Marketing for Ixekizumab in Adults with PsA
Also By This Author
  • Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

At the end of 2015, the Marketing Authorization Application for abaloparatide-SC to treat patients with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The manufacturer, Radius Health, is also developing abaloparatide-transdermal (abaloparatide-TD), which uses a patented transdermal technology, as a potential treatment for osteoporosis.

Baricitinib Receives European Marketing Approval
In February, the European Commission granted marketing approval in Europe for 2 and 4 mg baricitinib film-coated tablets (Olumiant) to treat moderate to severe active rheumatoid arthritis (RA) in adults who have responded inadequately to or are intolerant to at least one disease-modifying anti-rheumatic drug (DMARD). This approval is the first for baricitinib, which is now the first JAK inhibitor approved to treat RA in the European Union. The treatment was approved as a monotherapy or in combination with methotrexate.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Baricitinib is a once-daily, oral, selective and reversible JAK1 and JAK2 inhibitor. Clinical trials showed significant improvement in the signs and symptoms of RA with baricitinib compared with methotrexate and adalimumab plus methotrexate, which are standard-of-care therapies.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Radius Health. News release: Radius Health receives notification of PDUFA extension for abaloparatide-SC. 2017 Mar 10.
  2. Eli Lilly and Co. News release: European Commission approves once-daily Olumiant tablets for treatment of adults with moderate to severe active rheumatoid arthritis. 2017 Feb 13.

Filed Under: Drug Updates, Pharma Co. News Tagged With: abaloparatide, Abaloparatide-SC, baricitinib, Janus Kinase Inhibitors, Osteoporosis, postmenopause, Women

You Might Also Like:
  • Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis
  • FDA Approves Baricitinib for RA Patients
  • EU Approves Marketing for Ixekizumab in Adults with PsA
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.